IP Library Granted Patent US 9,206,457
Granted Patent B2
US 9,206,457 · App. 12/952,036 · Granted Dec 8, 2015

Utilization of pharmacological chaperones to improve manufacturing and purification of biologics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,206,457
App. No.
12/952,036
Granted
Dec 8, 2015
Kind
B2
Abstract

The present invention provides methods for improving the production of recombinant proteins through the use of pharmacological chaperones for the recombinant proteins. As exemplified by the present invention, the binding of a pharmacological chaperone to a recombinant protein expressed by a cell can stabilize the protein and increase export of the protein out of the cell's endoplasmic reticulum, and increase secretion of the protein by the cell.

Claims (10)

1. A method for improving the yield of an active recombinant human wild-type acid β-Glucosidase protein expressed by a host cell, wherein the host cell is in media having a pH greater than 5.0, which method comprises

contacting the host cell in vitro with isofagomine, wherein contacting the host cell with isofagomine increases activity of the acid β-Glucosidase secreted out of the cell, and

purifying the secreted acid β-Glucosidase from the media, wherein the isofagomine is contacted to the host cell in an amount effective to increase the yield stability of the active acid β-Glucosidase during purification,

wherein the isofagomine is present at a concentration of at least 3 μM.

2. The method of claim 1 , wherein the host cell is a mammalian cell.

3. The method of claim 1 , wherein the host cell is selected from the group consisting of CHO cells, HeLa cells, HEK-293 cells, 293T cells, COS cells, COS-7 cells, mouse primary myoblasts, and NIH 3T3 cells.

4. The method of claim 1 , wherein contacting the host cell with isofagomine increases the stability of the acid β-Glucosidase in the host cell media.

5. The method of claim 1 , further comprising storing the purified acid β-Glucosidase, wherein the isofagomine increases the stability of the acid β-Glucosidase during storage, and wherein the stability of the acid β-Glucosidase is greater than the stability of a recombinant human wild-type acid β-Glucosidase that is not contacted with isofagomine.

6. The method of claim 1 , wherein the secreted acid β-Glucosidase is purified to be at least 95% pure.

7. The method of claim 1 , wherein purifying the secreted acid β-Glucosidase comprises ammonium sulfate precipitation, column chromatography containing a hydrophobic interaction resin, contacting the secreted acid β-Glucosidase with a cation exchange resin, contacting the secreted acid β-Glucosidase with an anion exchange resin, or contacting the secreted acid β-Glucosidase with a chromatofocusing resin.

Assignments (2)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2013
From: DO, HUNG V.
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 031537/0647 →